AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

NexImmune Management to Present at Upcoming Conferences

April 5, 2019

GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be participating and presenting a corporate update at the following conferences:

Jefferies Immuno-Oncology Cell Therapy SummitFriday, April 5th, 3:05PM ETBoston, MA

Solebury Trout Private Company ShowcaseThursday, April 18th, 10:50AM ETBoston, MA

About NexImmuneNexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. For more information visit: www.neximmune.com

ContactChad RubinSolebury Trout+1 (646) 378-2947crubin@soleburytrout.com